Could Viking Therapeutics Become the Next Eli Lilly?
The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering transformative patient results and powering its stock to a spectacular 400% return in the past five years.
Amid this estimated $100 billion opportunity, much smaller upstart Viking Therapeutics (NASDAQ: VKTX) has emerged with a promising clinical pipeline, aiming to capture a share of the weight loss and metabolic disease market with its novel dual-agonist approach. Despite a long road ahead for this clinical-stage biotech, recent data suggesting that its VK2735 candidate could rival and even outperform the leading therapies highlights the significant potential of this exciting small-cap stock.
Could Viking Therapeutics be the next Eli Lilly? Here's what you need to know.
Source Fool.com
Viking Therapeutics Inc Stock
Our community is currently high on Viking Therapeutics Inc with 5 Buy predictions and 0 Sell predictions.
With a target price of 65 € there is potential for a 134.53% increase which would mean more than doubling the current price of 27.72 € for Viking Therapeutics Inc.
